Clinical Microbiology Newsletter最新文献_第7页

A special invitation to authors 对作者的特别邀请

Clinical Microbiology Newsletter Pub Date : 2023-09-01 DOI: 10.1016/j.clinmicnews.2023.09.002

引用次数: 0

A Brief Summary of the Current Role of Human Papillomavirus Testing in Cervical Cancer Screening 人类乳头瘤病毒检测在宫颈癌症筛查中的作用综述

Clinical Microbiology Newsletter Pub Date : 2023-08-15 DOI: 10.1016/j.clinmicnews.2023.08.002

Tam T. Van Ph.D., D(ABMM)

引用次数: 0

An Update on Schistosomiasis 血吸虫病研究进展

Clinical Microbiology Newsletter Pub Date : 2023-08-01 DOI: 10.1016/j.clinmicnews.2023.08.001

L. Payne , P.L. Chiodini , A.L. Bustinduy

{"title":"An Update on Schistosomiasis","authors":"L. Payne , P.L. Chiodini , A.L. Bustinduy","doi":"10.1016/j.clinmicnews.2023.08.001","DOIUrl":"10.1016/j.clinmicnews.2023.08.001","url":null,"abstract":"<div><p>Human schistosomiasis is caused by trematode parasites of the genus <em>Schistosoma</em>. Four species and two distinct clinical syndromes are relevant to humans, including <em>S. haematobium</em>, which is associated with urogenital schistosomiasis, whereas <em>S. mansoni, S. mekongi</em>, and <em>S. japonicum</em> are responsible for intestinal schistosomiasis. These flukes reside in the venous plexus of the human bladder and in mesenteric veins and release eggs that, when trapped in tissues, cause inflammation and fibrosis. More specifically, <em>S. mansoni, S. mekongi</em>, and <em>S. japonicum</em> can cause intestinal inflammation, hepatosplenic periportal fibrosis, portal hypertension, and esophageal varices that can bleed and cause death. In contrast, <em>S. haematobium</em>, a recognized carcinogenic organism, can drive bladder carcinoma and contribute to infertility and cervical cancer. Additionally, schistosomiasis can cause general anaemia, stunted growth, and cognitive impairment.</p><p>Despite the chronic complications associated with schistosomiasis, public awareness in areas of non-endemicity is limited, and travelers rarely consider risk of infection. We describe the diagnostics available in areas of endemicity, as well as in reference laboratories, to diagnose schistosomiasis in returning travelers or migrants to resource-rich locations.</p></div>","PeriodicalId":39211,"journal":{"name":"Clinical Microbiology Newsletter","volume":"45 15","pages":"Pages 125-132"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47232788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A special invitation to authors 对作者的特别邀请

Clinical Microbiology Newsletter Pub Date : 2023-07-15 DOI: 10.1016/j.clinmicnews.2023.07.004

引用次数: 0

Pharmacokinetic-Pharmacodynamic and Clinical Considerations for Extended- and Continuous-Infusion Antibiotics 长期和连续输注抗生素的药代动力学、药效学和临床考虑

Clinical Microbiology Newsletter Pub Date : 2023-07-15 DOI: 10.1016/j.clinmicnews.2023.07.003

Anne M. Masich Pharm. D., BCPS, Nicole E. Omecene Pharm. D., BCPPS, Jessica Lai Pharm. D. Candidate 2024, Ryan Ong Pharm. D. Candidate 2024, Leigh Anne Hylton Gravatt Pharm. D., BCPS, Rachel W. Khan Pharm. D., BCPS

{"title":"Pharmacokinetic-Pharmacodynamic and Clinical Considerations for Extended- and Continuous-Infusion Antibiotics","authors":"Anne M. Masich Pharm. D., BCPS, Nicole E. Omecene Pharm. D., BCPPS, Jessica Lai Pharm. D. Candidate 2024, Ryan Ong Pharm. D. Candidate 2024, Leigh Anne Hylton Gravatt Pharm. D., BCPS, Rachel W. Khan Pharm. D., BCPS","doi":"10.1016/j.clinmicnews.2023.07.003","DOIUrl":"10.1016/j.clinmicnews.2023.07.003","url":null,"abstract":"<div><p>Antibiotics are the most widely used treatment for infections yet there has been minimal antibiotic discovery in recent years despite rising drug resistance and treatment failures. A better understanding of antibiotic pharmacokinetics (PK) and pharmacodynamics (PD), along with the development of novel dosing strategies, such as extended (EI) and continuous infusions (CI), has helped to overcome these barriers. Studies have consistently demonstrated that EI/CI administration of beta-lactams and vancomycin in particular, improves PK-PD target attainment compared to intermittent infusions. However, the effects of EI/CI on clinical outcomes, including efficacy and safety, remain controversial. Emerging data focus on patient populations with altered PK that may benefit from EI/CI beta-lactams or vancomycin (e.g., critically ill, cystic fibrosis, or outpatient parenteral antibiotic therapy). Logistical barriers limit EI/CI use in practice, including intravenous access, drug stability and drug incompatibility. This review highlights beta-lactam and vancomycin PK-PD, EI/CI dosing strategies and relevant evidence for practice.</p></div>","PeriodicalId":39211,"journal":{"name":"Clinical Microbiology Newsletter","volume":"45 14","pages":"Pages 115-123"},"PeriodicalIF":0.0,"publicationDate":"2023-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48920380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical Microbiology Newsletter Pub Date : 2023-07-14 eCollection Date: 2023-01-01 DOI: 10.5334/cie.58

Livia Buratta, Elisa Delvecchio, Michele Capurso, Claudia Mazzeschi

{"title":"Health-Related Quality of Life in Children with Overweight and Obesity: An Explorative Study Focused on School Functioning and Well-being.","authors":"Livia Buratta, Elisa Delvecchio, Michele Capurso, Claudia Mazzeschi","doi":"10.5334/cie.58","DOIUrl":"10.5334/cie.58","url":null,"abstract":"<p><p>Overweight and obesity in childhood has reached epidemic levels, and their roles in physical and psychological health are now recognized. Recently, researchers have focused on the impact of these weight problems in health-related quality of life (HRQoL) domains, which are less investigated in children. This exploratory study examined the differences in HRQoL domains between a clinical group who were overweight/obesity treatment-seeking (n = 58) and a normal-weight group (n = 44) in a sample of 102 children, with a specific focus on school functioning and well-being. The second aim explored the link between our findings and other HRQoL dimensions. After controlling for sex and age, a multivariate analysis of variance showed lower levels in school functioning and well-being dimensions between overweight/obesity than normal-weight (F = 4.72; p < 0.05). Correlation analyses highlighted positive links between lower school functioning and well-being and lower levels of self-esteem (r = 0.308; p < 0.01) and social domains in terms of friendships (r = 0.522 ; p < 0.001) and family relationships (r = 0.561; p < 0.001) in children who were with overweight and obesity. This study discusses the implications of these findings in educational research and practices.</p>","PeriodicalId":39211,"journal":{"name":"Clinical Microbiology Newsletter","volume":"24 1","pages":"96-104"},"PeriodicalIF":0.0,"publicationDate":"2023-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11104352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78450189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Case-Based Review of Free-living Amebic Human Infections and Diagnosis 自由生活的阿米巴感染与诊断病例综述

Clinical Microbiology Newsletter Pub Date : 2023-07-01 DOI: 10.1016/j.clinmicnews.2023.07.001

Clare McCormick-Baw M.D., Ph.D. , Morgan Pence Ph.D., D(ABMM) , Laura Filkins Ph.D., D(ABMM)

引用次数: 0

A special invitation to authors 对作者的特别邀请

Clinical Microbiology Newsletter Pub Date : 2023-07-01 DOI: 10.1016/j.clinmicnews.2023.07.002

引用次数: 0

The Current Policy Debate around the Regulation of LDTs: What It Means for Infectious Disease Testing and Where It May Be Headed 当前关于最不发达国家监管的政策辩论:这对传染病检测意味着什么以及它可能走向何方

Clinical Microbiology Newsletter Pub Date : 2023-06-15 DOI: 10.1016/j.clinmicnews.2023.06.003

Mary Lee Watts

{"title":"The Current Policy Debate around the Regulation of LDTs: What It Means for Infectious Disease Testing and Where It May Be Headed","authors":"Mary Lee Watts","doi":"10.1016/j.clinmicnews.2023.06.003","DOIUrl":"10.1016/j.clinmicnews.2023.06.003","url":null,"abstract":"<div><p>The debate over federal regulation of diagnostic tests is not new, but scientific advances, societal developments, and global events over the past decade have accelerated efforts by the Food and Drug Administration (FDA) and members of Congress to revise the regulatory oversight of these devices, including laboratory-developed tests (LDTs). Despite years of congressional hearings and public meetings, legislation in the House and Senate, draft guidance from the FDA, and debate in the stakeholder community, LDT regulation remains unchanged, and the path forward remains unclear. LDTs play an essential role in infectious disease (ID) management and treatment, and changes in their regulation will have far-reaching implications for diagnostic laboratories. LDTs are widely used by clinical microbiology laboratories for the diagnosis and monitoring of a myriad infectious diseases, and until three years ago, such testing was conducted largely out of the spotlight. The COVID-19 pandemic changed this by bringing ID tests into the forefront. As the 118th Congress gets under way, the regulation and oversight of diagnostic tests, including LDTs, remains at the forefront of health care policy discussions on Capitol Hill and with the FDA. Change is coming, and it is important that clinical microbiologists, ID physicians, and other laboratorians have a seat at the table when such changes are being discussed.</p></div>","PeriodicalId":39211,"journal":{"name":"Clinical Microbiology Newsletter","volume":"45 12","pages":"Pages 95-100"},"PeriodicalIF":0.0,"publicationDate":"2023-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48950779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Review of Diagnostic Modalities of Four Common Bacterial Tickborne Illnesses in the United States 美国四种常见细菌性蜱传疾病的诊断方法综述

Clinical Microbiology Newsletter Pub Date : 2023-06-01 DOI: 10.1016/j.clinmicnews.2023.06.001

Daisy Fernandez M.P.H. , Suha Abu Khalaf M.D. , Andres Bran M.D.

引用次数: 0